Compare Biogen Inc (BIIB) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Plug Power Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.60B), while Plug Power Inc trades at $2.22 (market cap $2.94B). The key difference: Biogen Inc is far larger — about 10.4× Plug Power Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | PLUG | |
|---|---|---|
Market Cap | $30.60B | $2.94B |
Sector | Health | Industrials |
52-Week High | $216.63 | $4.14 |
52-Week Low | $128.00 | $1.41 |
Enterprise Value | $37.67B | $3.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.94, up 0.8% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $234.47. The company has beaten earnings estimates for three consecutive quarters, including Q2 2026 EPS of $3.60 versus $2.94 expected, and recently completed the acquisition of RayThera Inc. to bolster its immunology pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%.
The outlook is positive, driven by strong execution and growth from newer drugs like Leqembi, though risks include pressure on legacy multiple sclerosis sales and a high P/E ratio of 36.93. The stock offers potential upside to the analyst target but faces earnings volatility and integration risks from recent acquisitions.
Plug Power (PLUG) trades at $2.18, up 5.31% with a bearish technical signal despite recent earnings beat. The company shows improving operational metrics with reduced cash usage and margin improvements, though it remains unprofitable with negative gross margins of -25.66%. Management targets positive EBITDA by Q4 2026 while navigating significant liquidity challenges through asset sales and financing activities.
While analyst consensus leans bullish with a $2.22 price target, PLUG faces substantial execution risks amid persistent losses and cash burn. The stock offers speculative upside if management delivers on profitability targets, but investors face elevated risk from the company's negative cash flow and competitive hydrogen market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
